doi:10.3969/j.issn.1004-583X.2022.11.016

Abstract

CLC Number:

R563.9

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.11.016

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I11/1048

References 37

[1]	Li Y, Li Y, Wu J, et al. Predictors of poor outcome of anti-MDA5-associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis[J]. J Immunol Res, 2020, 2020: 2024869.
[2]	Lian X, Zou J, Guo Q, et al. Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: The FLAIR model[J]. Chest, 2020, 158(4): 1535-1545. doi: 10.1016/j.chest.2020.04.057 pmid: 32428508
[3]	Gan YZ, Zhang LH, Ma L, et al. Risk factors of interstitial lung diseases in clinically amyopathic dermatomyositis[J]. Chin Med J (Engl), 2020, 133(6): 644-649.
[4]	Gui X, Ma M, Ding J, et al. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis[J]. Rheumatology (Oxford), 2021, 60(8): 3913-3922. doi: 10.1093/rheumatology/keaa843 pmid: 33501503
[5]	Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA 5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA 5 antibody-positive dermatomyositis[J]. Rheumatology (Oxford), 2012, 51(9): 1563-1570. doi: 10.1093/rheumatology/kes102 URL
[6]	Hozumi H, Fujisawa T, Nakashima R, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease[J]. Respir Med, 2016, 121: 91-99. doi: S0954-6111(16)30282-7 pmid: 27888997
[7]	Dias Junior AG, Sampaio NG, Rehwinkel J. A balancing act: MDA5 in antiviral immunity and autoinflammation[J]. Trends Microbiol, 2019, 27(1): 75-85. doi: S0966-842X(18)30179-3 pmid: 30201512
[8]	Nishina N, Sato S, Masui K, et al. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease[J]. RMD Open, 2020, 6(2): 001202.
[9]	Takeuchi O, Akira S. MDA5/RIG-I and virus recognition[J]. Curr Opin Immunol, 2008, 20(1): 17-22. doi: 10.1016/j.coi.2008.01.002 pmid: 18272355
[10]	Kawasumi H, Katsumata Y, Nishino A, et al. Association of serum soluble CD163 with polymyositis and dermatomyositis, especially in anti-MDA5 antibody-positive cases[J]. J Rheumatol, 2018, 45(7):947-955. doi: 10.3899/jrheum.170997 pmid: 29657141
[11]	Peng Y, Zhang S, Zhao Y, et al. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis[J]. Clin Rheumatol, 2018, 37(1):107-115. doi: 10.1007/s10067-017-3799-y pmid: 28842784
[12]	Shimizu T, Koga T, Furukawa K, et al. IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis[J]. J Intern Med, 2021, 289(2): 206-220. doi: 10.1111/joim.13154 URL
[13]	He C, Chen J, Luo X, et al. Evaluation of biomarkers related to endothelial dysfunction: Proof of vasculopathy in anti-melanoma differentiation-associated gene 5 dermatomyositis[J]. Clin Exp Rheumatol, 2021, 39(1):151-157. doi: 10.55563/clinexprheumatol/ubov8b pmid: 32896243
[14]	武雅楠, 王颖嫒, 祁福敏, 等. 抗黑色素瘤分化相关蛋白-5抗体阳性炎性肌病临床特征分析[J]. 中华风湿病学杂志, 2022, 26(02):105-114.
[15]	Sato S, Kuwana M, Fujita T, et al. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease[J]. Mod Rheumatol, 2013, 23(3): 496-502. doi: 10.1007/s10165-012-0663-4 pmid: 22644102
[16]	Matsushita T, Mizumaki K, Kano M, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis[J]. Br J Dermatol, 2017, 176(2):395-402. doi: 10.1111/bjd.14882 pmid: 27452897
[17]	Zhang SH, Zhao Y, Xie QB, et al. Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis[J]. Br J Dermatol, 2019, 180(5):1090-1098. doi: 10.1111/bjd.16917 pmid: 29947075
[18]	鞠伟威, 王培绒, 杨国欢, 等. 抗MDA-5抗体阳性炎性肌病合并间质性肺病的临床特点和预后分析[J]. 国际呼吸杂志, 2022, 42(4):267-274.
[19]	Li J, Liu Y, Li Y, et al. Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: A systematic meta-analysis[J]. J Dermatol., 2018, 45(1):46-52. doi: 10.1111/1346-8138.14092 URL
[20]	陈望, 史晓飞, 陈殿森, 等. 抗黑色素瘤分化相关基因5抗体阳性皮肌炎的胸部高分辨率CT分析与临床特征[J]. 中华风湿病学杂志, 2022, 26(1):22-26.
[21]	Tanizawa K, Handa T, Nakashima R, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody[J]. Respir Med, 2011, 105(9): 1380-1387. doi: 10.1016/j.rmed.2011.05.006 pmid: 21632230
[22]	Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis[J]. Rheumatology (Oxford), 2018, 57(12): 2114-2119. doi: 10.1093/rheumatology/key188 pmid: 30060040
[23]	Zuo Y, Ye L, Chen F, et al. Different multivariable risk factors for rapid progressive interstitial lung disease in anti-MDA5 positive dermatomyositis and anti-synthetase syndrome[J]. Front Immunol., 2022, 13:845988. doi: 10.3389/fimmu.2022.845988 URL
[24]	Jiang L, Wang Y, Peng Q, et al. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody[J]. Clin Rheumatol, 2019, 38(6): 1655-1663. doi: 10.1007/s10067-019-04457-w pmid: 30739212
[25]	Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis[J]. Arthritis Rheumatol, 2020, 72(3): 488-498. doi: 10.1002/art.41105 URL
[26]	Matsuda KM, Yoshizaki A, Kuzumi A, et al. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis[J]. J Dermatol, 2020, 47(5):483-489. doi: 10.1111/1346-8138.15274 URL
[27]	Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease[J]. N Engl J Med, 2019, 381(3): 291-293. doi: 10.1056/NEJMc1900045 URL
[28]	Zhang X, Zhou S, Wu C, et al. Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis[J]. Rheumatology (Oxford), 2021, 60(7):227-228.
[29]	So H, Wong VTL, Lao VWN, et al. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis[J]. Clin Rheumatol, 2018, 37(7): 1983-1989. doi: 10.1007/s10067-018-4122-2 pmid: 29713969
[30]	Ge Y, Li S, Tian X, et al. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy[J]. Clin Rheumatol, 2021, 40(6): 2311-2317. doi: 10.1007/s10067-020-05530-5 pmid: 33411136
[31]	Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease[J]. Semin Arthritis Rheum, 2020, 50(4):776-790. doi: 10.1016/j.semarthrit.2020.03.007 URL
[32]	Sasaki N, Ishii A, Kurabayashi T, et al. Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease[J]. Mod Rheumatol Case Rep, 2021, 5(1):87-94.
[33]	Yamagata A, Arita M, Tanaka A, et al. Therapeutic plasma exchange for clinically amyopathic dermatomyositis (CADM) associated with rapidly progressive interstitial pneumonia[J]. J Clin Apher, 2020, 35(5):435-443. doi: 10.1002/jca.21824 URL
[34]	Huang K, Vinik O, Shojania K, et al. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: A case-based review[J]. Rheumatol Int, 2019, 39(11): 1971-1981. doi: 10.1007/s00296-019-04398-2 pmid: 31375890
[35]	Leclair V, Labirua-Iturburu A, Lundberg IE. Successful lung transplantation in a case of rapidly progressive interstitial lung disease associated with antimelanoma differentiation-associated gene 5 antibodies[J]. J Rheumatol, 2018, 45(4):581-583. doi: 10.3899/jrheum.171047 pmid: 29606647
[36]	Deitchman AR, Kalchiem-Dekel O, Todd N, et al. Rapidly progressive interstitial lung disease due to anti-melanoma differentiation associated protein-5 requiring a bilateral lung transplant, and complicated by kennel cough[J]. Respir Med Case Rep, 2019, 28:100886.
[37]	Marchiset A, Neuville M, Voiriot G, et al. High-emergency lung transplantation for interstitial lung disease associated with anti-MDA5 dermatomyositis: A case report[J]. Transplant Proc, 2021, 53(8):2613-2615. doi: 10.1016/j.transproceed.2021.08.012 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 37

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2024, 39(2): 188-192.
[2]	. [J]. Clinical Focus, 2023, 38(8): 749-752.
[3]	Sun Ying, Yu Qin. Long-term effect of hypoglossal nerve stimulation in the treatment of obstructive sleep apnea hypopnea syndrome: A meta analysis [J]. Clinical Focus, 2022, 37(8): 677-684.
[4]	Wang Xuefeng. Clinical correlation between fatigue and multi-dimensional indexes in patients with stable moderate chronic obstructive pulmonary disease [J]. Clinical Focus, 2022, 37(8): 704-707.
[5]	Zhang Zhiping, Zhang Baomin, Qin Wei, Gao Lingjie, Chen Dong. Clinical application of nutritional support on mechanical ventilation in acute exacerbation of chronic obstructive pulmonary disease [J]. Clinical Focus, 2022, 37(6): 510-514.
[6]	. [J]. Clinical Focus, 2021, 36(9): 861-864.
[7]	Fu Qun, Guo Di, Zhao Wenfei. VEGF, ICAM-1, IL-13, FeNO level of induced sputum on asthma, asthma-copd overlap, and chronic obstructive pulmonary disease in patients: clinical changes and significance [J]. Clinical Focus, 2021, 36(6): 513-516.
[8]	Zhang Qinxia, a, Zhang Haifu, b, Lyu Quna. Efficacy and safety of ticagrelor in coronary artery disease and chronic obstructive pulmonary disease: a metaanalysis [J]. Clinical Focus, 2020, 35(11): 965-970.
[9]	. [J]. Clinical Focus, 2016, 31(3): 345-348.
[10]	Lu Qiuxia;Chen Xi;Wu Xiao;Hu Shanyou;Wang Li. Plasma N-terminal B-type natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease patients and prognosis [J]. Clinical Focus, 2015, 30(11): 1265-1268.
[11]	. [J]. Clinical Focus, 2015, 30(9): 1063-1066.
[12]	. @@ [J]. Clinical Focus, 2015, 30(8): 956-960.
[13]	Zhang Zhen;Jia Shiqiang;Peng Zhanxian;Zong Wei;Wen Shiwei;Sun Luhua;Rong Xuebing;Wang Jingjun;Dong Shimin. Clinical value of rapid shallow breathing index in predicting ventilator weaning in sleeping patients with acute exacerbation chronic obstructive pulmonary disease [J]. Clinical Focus, 2015, 30(5): 506-508509.
[14]	. [J]. Clinical Focus, 2015, 30(5): 564-566.
[15]	Hu Shanshan;Zhang Shun;Cai Ting. Immunochemotherapy for advanced non-small cell lung cancer:a meta-analysis [J]. Clinical Focus, 2015, 30(3): 283-289.